Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06589310
Recruiting Observational

Falcon Real World Evidence Registry

NCT06589310 · tracked via the Priya Life Science USA tracker
Sponsor
Exact Sciences Corporation
Phase
Observational
Started
2024-08-01
Last updated
2026-09-11

Condition(s) studied

Cancer

Investigational drug(s) / intervention(s)

Exact Sciences Multicancer Early Detection (MCED) Test

Exact Sciences Multicancer Early Detection (MCED) Test: Exact Sciences MCED test, is a qualitative in vitro diagnostic (IVD) for the detection of alterations in circulating tumor DNA and tumor-associated protein levels, which are commonly associated with cancer. It is performed on plasma derived from peripheral blood specimens.

Study summary

This is a multi-site registry of patients receiving the Exact Sciences Multicancer Early Detection (MCED) test.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Participant age at time of consent is between 50 and 80 years * Agree to receive the Exact Sciences MCED test and follow-up imaging * Willing and able to provide informed consent * Access to a suitable technology and willing to complete surveys electronically Exclusion Criteria: * Any invasive tumor (excluding non-melanoma skin cancers) or hematological malignancy in the previous three years or current suspicion of cancer and/or in active treatment (e.g., chemotherapy, radiation therapy, immunotherapy, and/or surgery

Primary outcome measure(s)

  • Vital status — Up to 5 years
    Particpant is alive or deceased
  • Cancer status — Up to 5 years
    Presence or absence of cancer

Trial sites (2)

FacilityCityRegionStatus
Endeavor Health Evanston Illinois Recruiting
Baylor Scott & White Health Dallas Texas Recruiting

More Exact Sciences Corporation trials in the USA

CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer Active, not recruiting
Endometrial Cancer Vaginal Fluid Specimen Collection Study Active, not recruiting
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) Recruiting
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk Active, not recruiting
Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality Active, not recruiting

Other trials for the same condition

A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data Recruiting
Galleri® in the Medicare Population. Recruiting
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors Active, not recruiting
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device Active, not recruiting
Met Non Small Cell Cancer Registry (MOMENT) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06589310 on ClinicalTrials.gov ↗ ← All trials in the USA